Abstract
Research into bioprosthetic heart valve (BHV) materials seeks to enhance durability and biocompatibility, particularly by mitigating vascular calcification (VC). VC entails hydroxyapatite deposition in blood vessel walls through vascular smooth muscle cells (VSMCs) phenotypic switching to osteogenic differentiation, driven by pro-calcific signals that might be inhibited by fetuin-A. To our knowledge, no prior studies have reported fetuin-coated bovine vein tissue for this purpose. This study aimed to evaluate the cytotoxicity, biocompatibility, and anti-calcification potential of fetuin-coated biomaterial. The effectiveness of fetuin coating on biomaterial was characterized using photoluminescence (PL), FTIR and Raman spectroscopy, while fetuin release was quantified. Biocompatibility was evaluated in vitro on VSMCs and human iliac artery endothelial cells (HIAE-78T) and in vivo by subcutaneous implantation in Wistar rats. The effects of fetuin were investigated in two in vitro calcification models based on 2 mM inorganic phosphate, or 10 mM β-glycerophosphate in an organic model. The induction of osteogenic markers such as osterix, bone morphogenic protein 2, and collagen type 1, osteocalcin and osteopontin, was assessed at both the mRNA and protein levels. Detoxification of glutaraldehyde-fixed biomaterial using glycine and NaBH₄ eliminated cytotoxicity, markedly enhancing biocompatibility toward VSMCs, HIAE-78T and subcutaneous rat implants, which showed no acute rejection and preserved structural integrity. Fetuin coating, with ~30% sustained release over three weeks, significantly inhibited mineralization on non-cellular and organic VSMCs models by decreasing mineral deposition, osteogenic markers expression. These results position fetuin-coated bovine vein biomaterial as a novel, promising anti-calcification strategy enhancing long-term durability and cardiac valves safety.